Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis (whole cell), hepatitis B and haemophilus influenzae type b vaccine (GSK)
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-Hib is a pentavalent combination vaccine designed for pediatric immunization, providing protection against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive Haemophilus influenzae type b (Hib) infections. The vaccine formulation typically includes purified diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis organisms, recombinant hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a carrier protein, such as tetanus toxoid. By combining these antigens into a single injection, the vaccine simplifies immunization schedules, reduces the number of injections required for infants, and improves coverage in global health programs. It is widely utilized in low- and middle-income countries and is a cornerstone of the Expanded Programme on Immunization (EPI) supported by organizations like Gavi and UNICEF.
- Brand names
- QuinvaxemEasyfive-TTPentabioQuintanrixTritanrix-HepB/HibComBE FiveShan5Shan-5Shan 5
- Other names
- DTwP-HepB-HibDTP-HB-Hibpentavalent vaccineDiphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed)
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis (whole cell), hepatitis B and haemophilus influenzae type b vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis (whole cell), hepatitis B and haemophilus influenzae type b vaccine (GSK).